← Latest papers
📄 molecular biology

FTO does not function as an m6A eraser in AML: a reassessment using direct RNA nanopore sequencing

Using direct RNA nanopore sequencing, this study challenges the prevailing view that FTO acts as an m6A eraser in AML and other contexts, demonstrating instead that FTO primarily demethylates m6Am in snRNAs while having minimal impact on mRNA m6A levels.

Original authors: Nicholson, L. S., Guimaraes-Teixeira, C., Liu, J. F., Chien, R., Xu, J., Poh, H. X., Pan, Y.-X., Jaffrey, S. R.

Published 2026-10-26 (v2)
📖 4 min read☕ Coffee break read

Original authors: Nicholson, L. S., Guimaraes-Teixeira, C., Liu, J. F., Chien, R., Xu, J., Poh, H. X., Pan, Y.-X., Jaffrey, S. R.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Inside the cells of every living thing, from the smallest bacterium to the human brain, a complex system of chemical tags sits upon the genetic instructions carried by RNA. These tags act like sticky notes, telling the cell when to read a message, how long to keep it, and how to translate it into protein. One of the most common and important of these tags is a tiny methyl group attached to a specific letter in the RNA code. Scientists call this modification m6A. For years, the prevailing belief in the field was that this tag was dynamic and reversible, constantly being added and removed by specific enzymes to control cell behavior. The most famous enzyme thought to perform this removal was called FTO. In the context of acute myeloid leukemia, a dangerous blood cancer, researchers had become convinced that FTO acted as a precise eraser, stripping the methyl tag from specific cancer-driving genes like MYC. This idea suggested that by blocking FTO, doctors could stop the cancer from growing, leading to the development of drugs designed to inhibit the enzyme.

A team of researchers at Weill Cornell Medicine and other institutions decided to test this widely accepted model with a level of precision that had not been possible before. They turned to a new technology called direct RNA nanopore sequencing. Unlike older methods that relied on antibodies to grab onto tagged RNA and estimate how much was there, this new approach reads the RNA molecule directly, allowing scientists to count exactly how many copies of a specific gene carry the tag and how many do not. This gives a precise measurement of the tag's presence, known as stoichiometry, rather than just a rough estimate. The researchers applied this technology to leukemia cells, first removing the FTO enzyme genetically and then treating the cells with a drug designed to block it. They also looked at brain tissue and other cell types to see if the pattern held true elsewhere.

The results were striking and contradicted the established narrative. When the researchers removed or blocked FTO in leukemia cells, the amount of the m6A tag on the MYC gene and other cancer-related transcripts did not change. The precise measurements showed that the tag remained at the same level whether the enzyme was present or absent. In fact, across the entire genetic landscape of these cells, there was no evidence that FTO was selectively removing tags from specific messages. The data suggested that FTO does not function as the precise eraser of m6A on mRNA that it was thought to be. Instead, the researchers found that when FTO was removed, a different chemical tag, called m6Am, which sits on the very beginning of small RNA molecules involved in processing other genes, increased dramatically. This tag is found on small nuclear RNAs, which are essential for the cell's internal machinery. The increase in m6Am was consistent and robust across all the cell types and tissues they tested, including the leukemia cells, mouse brain, and human kidney cells.

The study also re-examined the biological importance of FTO in leukemia survival. Previous work had suggested that leukemia cells could not survive without FTO, which is why blocking it was thought to be a viable treatment strategy. However, when the researchers analyzed large databases of genetic experiments and tested the cells themselves, they found that leukemia cells grew and survived just fine even when FTO was completely removed. Furthermore, they discovered that the drug FB23-2, which was believed to kill leukemia cells by blocking FTO, continued to stop cell growth even in cells that lacked the FTO enzyme entirely. This indicates that the drug's effect comes from hitting a different target, not from inhibiting FTO.

These findings suggest that the biological effects previously attributed to FTO removing m6A tags from cancer genes may actually be driven by its role in managing the m6Am tag on small RNA molecules. While FTO can remove the m6A tag in a test tube, the study indicates that in living cells, it does not do so in a way that significantly alters the genetic messages that drive cancer. The researchers conclude that the idea of FTO as a site-specific eraser of m6A in mRNA is likely incorrect, and that the focus of future research and drug development should shift toward understanding the true role of FTO in regulating m6Am and the small RNA molecules it modifies.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →